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Abstract
The biopharma industry is in crisis, demonstrated by unsustainable research and 
development (R&D) costs. In parallel, the healthcare system suffers from skyrocket-
ing costs, driven by the prevalence of chronic diseases and increased life expectancy. 
Innovative technologies have the potential to alleviate challenges both in the bio-
pharma R&D model and in healthcare. This chapter considers how Big Data analysis 
based on artificial intelligence and machine learning offer opportunities to drive 
greater efficiency across the entire R&D value chain, enhance the quality of assets 
produced, and improve the time and cost to bring products to market. We also con-
sider the unique challenges that arise with the integration of these fields into healthcare 
and medicine, specifically, the initially high costs when new medical and healthcare 
technologies are brought to the marketplace; widening socioeconomic health inequali-
ties due to high marketplace costs; and unique methodological challenges presented by 
cross industry innovation, research, development, and implementation.
Keywords: artificial intelligence, healthcare, biopharma industry, personalized 
medicine, big data, digital transformation, machine learning, R&D, innovation
1. Introduction
The biopharma industry is facing significant challenges reflected by unsustainable 
research and development (R&D) costs. This challenge is seen in several ways. First, 
aggressive pricing pressure has led to an increase in the cost needed to bring products to 
market—from $1.188 billion in 2010 to a record level of $2.168 billion in 2018. A second 
major reason is the threat of patent expirations on numerous blockbuster drugs. As a 
result, biopharma companies experienced record low R&D returns in 2018—10.1% in 
2010 to 1.9% in 2018, the lowest levels the industry has seen in 9 years [1].
In parallel to biopharma challenges, the healthcare system is having a crisis 
due to the prevalence of chronic diseases and increased life expectancy, the main 
causes for skyrocketing healthcare costs (in US, the health share of GDP is 18% and 
expected to reach 19.6% by 2014) [2]. Today, 50% of the entire US population is 
considered chronic patients, which accounts for 85% of the overall cost of health-
care [3]. Fortunately, the majority of chronic diseases can be prevented or delayed 
until significantly later stages in life due to successful medical interventions.
Today, the healthcare industry is seeing an integration of novel genetic and digi-
tal technologies that help identify and cope with the complexity of chronic diseases 
and their often “silent” transition from healthy status to an active disease with a 
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late onset of symptoms. The challenge is to move medical interventions upstream 
to the pre-disease state, during which symptoms are cheaper and easier to treat. 
Significant change must be made to the current pharma R&D model, if productiv-
ity and profitability are ever to be restored and maximized. The view today is that a 
complete digital transformation is what is needed to achieve these goals and deliver 
the next generation of scientific breakthroughs.
Big Data analysis based on artificial intelligence (AI) and machine learning 
(ML) offer opportunities to address some of these challenges expected to drive 
greater efficiency across the entire R&D value chain, and eventually improve the 
quality of the assets produced, as well as the time and cost it takes to bring them 
to the market. The change is already beginning to take place. In fact, most of the 
big pharma companies (such as Novartis, Roche, Pfizer, Merck, AstraZeneca, 
GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, Johnson & Johnson, etc.) 
are already on the road to taking advantage of AI innovation (healthcareweekly.
com, online) as it becomes a driving force in the innovation of medicine and 
healthcare.
AI is a growing industry of personalized health technology, or personalized 
medicine, which will have tremendous effect on healthcare management. The key 
idea behind the technological personalization of medicine and healthcare is to 
capture, analyze, and utilize individual patient characteristics, such as biomarkers, 
then to base medical decisions on these individual characteristics rather than on 
population averages. Another direct application is the technological development 
of assisted devices that augment traditional medical practice and healthcare, such 
as the broad use of robotics as well as patient-worn devices (“wearables”) that 
optimize care. This chapter reviews leading publications in these areas and outlines 
major advantages and also methodological and clinical weak points that need to be 
addressed in order for personalized medicine to realize its potential.
2. Toward personalized medicine age
Advances in technology are shifting the practice of medicine from anecdotal 
to data-driven. Due to this shift, improvement in screening, prediction, diagnosis, 
and the treatment of disease has increased the quality of medical care worldwide 
and cost effectively ([4]: p. 139). Personalized medicine is generally recognized as 
promising and advantageous in several important ways. It can improve the efficacy 
of medication as treatments become better matched to patients; when patients are 
better matched to treatments, ineffective treatments and their accompanying harm-
ful side effects are avoided; healthcare costs are driven down as a result of better 
use of therapies; diseases are detected sooner or even anticipated so care is shifted 
from detection to prevention, thereby avoiding late-care, less effective, and more 
costly treatment; disease management is more effective through wearable patient 
technology; and clinical trials can be more accurate as patient selection becomes 
more precise ([5]: pp. 1-2).
Despite these apparent advantages, the technological personalization of 
medicine brings numerous challenges that must be addressed in order to harness 
its full potential. When healthcare and medical technologies first enter the mar-
ketplace, for example, they are often initially more expensive, as the companies 
that develop these products need to recoup high expenses from R&D. As a result, 
personalized health technologies are utilized first by the more affluent, driving 
an even larger wedge between affluent populations and marginalized ones. This 
serves to broaden the already wide socioeconomic gap in health inequalities in the 
short term ([5]: p. 2).
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Solutions must be found to provide for diverse socioeconomic patient access to 
personalized medicine, so that its benefits reach all populations. This is especially 
important as marginalized and disadvantaged populations are precisely the ones 
least likely to access and utilize these products, but typically the very populations 
that would disproportionally benefit from them. Early disease diagnosis and 
management provided by advances in personalized medicine are especially needed 
in these populations and innovating for these populations is crucial in order for 
personalized health technology to reach its public health potential. For this, cre-
ative, strategic health initiatives must be developed that aim to lower costs while 
expanding access ([6]: pp. 2–4).
3. Challenges of human-machine innovation
The challenge in personalized medicine is methodological and inherent in cross-
industry innovation itself—the ways in which different technologies are utilized for 
healthcare and medicine. While machine learning techniques can process complex 
and large data and provide accurate predictions based on this analysis, they are 
unable to provide a deeper understanding of phenomena ([6]: p. 5). In this way, 
Data Science and AI do not replace classical research. As a result, there remains a 
gap between the potential of personalized medicine and its realized application 
borne out as solutions that impact clinical practice.
One foreseeable way to bridge this gap is to push for a better coordinated inter-
disciplinary effort. Scientists, physicians, patients and their advocates, regulatory 
agencies, and health insurance providers need to create a healthcare system that 
can learn and adapt as it develops ([6]: p. 12). In short, technology is not meant to 
replace physicians. Rather, the idea is to provide physicians with a tool that supports 
their decisions based on the accurate processing, understanding, and analysis of 
large amounts of already available biomedical data ([6]: p. 13).
Another way to understand this difficulty is that personalized medicine is 
“underpinned” by convergent, cross-industry innovation. This naturally results 
in complexity, and uncertainty in terms of organization ([7]: p. 44). The question 
becomes how best to innovate given this challenge of cross-industry integration.
The two dominant forms of organizational learning aim for simplification and 
specialization. This is especially so in the context of uncertainty and complex inte-
gration issues that arise from innovation in an emerging cross-industry ecosystem. 
However, new research suggests a need to face this complexity via an adaption of a 
multitude of approaches, recognizing that uncertainty and risk are part and parcel 
of the very nature of innovation.
In this context, the management of risk might best be replaced with addressing 
uncertainty, understanding that in an emerging ecosystem of convergent innova-
tion, comprehensive understanding is lacking. Approaches that embrace complexity 
rather than just managing it might prove more effective, specifically by adopting 
numerous measures to address the divergent factors in cross-industry innovation 
([7]: pp. 51–52).
4. AI and digital healthcare case study: AI for cardiac patients
As a case in point, consider the impact of AI in cardiology and cardiac imaging. 
Machine learning and the “deep” neural networks used for this purpose hold great 
promise when applied to medical imaging. Improving the identification accuracy in 
patients at risk for cardiovascular events is critical, as well as patients who are not at 
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risk but suffer from misdiagnosis and are given unnecessary and sometimes harm-
ful treatments with negative side effects. The importance of improving the accuracy 
in detection and diagnosis is thus monumental given that cardiovascular disease is 
leading cause of death worldwide ([4]: p. 139).
The use of AI in cardiology has increased dramatically in the past 5 years. 
Machine learning algorithms now outperform many traditional algorithms, includ-
ing the established risk prediction algorithm used by the American College of 
Cardiology (ACC)/American Heart Association (AHA), performing with a 3.6% 
predictive accuracy improvement over the ACC/AHA algorithm ([4]: p. 139).
Still major challenges lie ahead. Before AI can reliably be utilized by any 
field of medicine let alone realize its potential for cardiac patients, the neural 
networks necessary for its application require constant and extremely time-
consuming expansion and revision. Key difficulties are (i) the extremely large 
amount of training data required by neural networks; (ii) the need to annotate 
(label) any dataset used for the training of a neural network; (iii) creating an 
understating of what computers learn given that the patterns and knowledge 
gained by a network are contained in the weights of the nodes of the network; 
and (iv) the risk of “overfitting” the training data when designing and training a 
neural network.
In other words, better efficiency of machine learning, together with improved 
accuracy with less training and data necessary, are all needed in order to approxi-
mate the efficiency of human learning and bring its relevance to a clinical setting.
Given these challenges, AI in cardiac CT angiography has made tremendous 
gains in the past 10 years, and over the next 10 years, the expectation is that we 
will see more AI software development and use in cardiac imaging than in the past 
50 years ([4]: p. 139).
5. Decision-making tools for practitioners
A recent study revealed that one in every 71 cases from 6000 tissue samples of 
cancer patients across the US was misdiagnosed and up to one in five were misclas-
sified. This same study reviewed 25 years of US malpractice claims and concluded 
that diagnostic errors were the cause of the most severe patient harm. According to 
the National Academies’ Institute of Medicine, 10% of patient deaths and as much 
as 17% of hospital complications are a result of diagnostic errors ([8]: p. 1).
What is more, it was not primarily the physicians who were the cause of most 
diagnostic errors. Instead, the study found, the fault lies primarily in substandard 
collaboration and synthesis of information in the healthcare system as well as 
communication gaps, and that the healthcare system as a whole failed to effectively 
support the diagnostic process ([8]: p. 1).
Now let us consider the application of AI to address the need for collaboration 
and integration in healthcare to improve the diagnostic process. Optum, a lead-
ing company providing these solutions for the healthcare industry, developed a 
program called Care Coordination Platform. It processes vast amounts of data and 
provides a comprehensive overview of every patient’s full medical history, allowing 
healthcare providers an immediate, complete picture of each patient. The platform 
suggests the most appropriate and cost-effective treatment options; identifies high-
risk patients before symptoms occur; and has adaptive algorithms that incorporate 
clinical data, claims, and socioeconomic figures ([8]: p. 2).
A recent study examined the effects of clinical decision-support sys-
tems (CDSSs) on practitioner performance and patient outcomes. Clinical 
decision- support tools made available to practitioners and patients, such as 
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computer-generated clinical knowledge and patient-related information, were 
studied. When such data are filtered and made available at appropriate times, 
it was shown to enhance patient care. CDSS can also send reminders, warn-
ings, test results, check for drug interactions, dosage errors, contraindications, 
and list patients eligible for specific interventions such as immunizations and 
follow-ups [9].
The study found that CDSSs that require large amounts of data entry adversely 
affect physician satisfaction and use of the system. When large amounts of data 
required for the CDSS to be effective are incomplete, diagnoses will be less accurate, 
or it will take longer to complete the data, resulting in delays in the CDSS to accu-
rately deliver advice. Anticoagulant-prescribing CDSSs are a case in point; the data 
required are more complex and have a higher patient variance.
CDSSs requiring limited number of patient data items for input were the most 
used and clinically successful. Examples include preventative care reminder systems 
for routine tasks such as blood pressure tests, pap smears, vaccinations, etc.
The study concluded that CDSSs become more effective as they become more 
specified and sensitive in their levels of advice but at the same time the manual 
input of data needs to be minimized, and the CDSS advice needs to be available in a 
timely manner to be of relevance for physician use.
6. Advanced genetic technologies
Personalized medicine is making an impact in advanced genetic technologies as 
well. Genome modulation (modifications), in particular, has an array of applica-
tions, from energy, food, and industrial to medical. Researchers are turning to 
genome modulation with the hope that it will provide the key to understanding and 
answering some of life’s most difficult and challenging questions.
Genome modulation applied medically has been known as gene therapy, but 
with new technologies, has evolved into the science of gene editing. At the forefront 
of this technology is what is now known as Clustered Regularly Interspaced Short 
Palindromic Repeats, or CRISPR. Experts claim CRISPR has brought with it new 
streams of business based on its cutting-edge technologies [10].
One recent example of CRISPR technology application is the correction of blood 
clotting problems in newborn and adult mice, with marked success. The aim is to cure 
the majority of patients with hemophilia B with CRISPR-based gene targeting [10].
Growing interest in CRISPR technology is speeding its transition to research, 
clinical trials, and applications in humans, and it was recently tested on a human 
being for the first time. In China, a patient diagnosed with terminal lung cancer 
was treated with CRISPR gene editing therapy as part of a clinical trial. Meanwhile, 
clinical trials in the United States using CRISPR technology are underway.
CRISPR technology has opened channels for business, but there are still many 
daunting challenges before its application can be realized clinically. One such 
hurdle, if not the most significant one, is regulation. Personalized medicine, 
including gene editing technologies, is involved in a regulatory business, involving 
peer-reviewed, published papers and clinical trials. Even in cooperation with the 
FDA, for example, it could still take a new technology 20 years to be approved.
7. Robotics and advanced medical devices
Another way in which personalized medicine is driven by advancements in 
technology is in healthcare robotics. The introduction of robotics in healthcare is 
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driven by the desire to improve quality, safety, and control expenditure. Surgical 
robots, service robots, companion robots, cognitive therapy robots, robotic limbs 
and exoskeletons, humanoids, and rehabilitation robots are just a few applied areas 
already making use of this technology.
Despite clear advantages and a promising, growing future of robotics in health-
care and in medical devices, there is a need for a robotics strategy that addresses 
concerns and challenges. Patient and cultural perceptions, liability rules, and 
ethical debates present challenges to the integration and development of robotics in 
healthcare.
A recent study suggested that a deliberative approach is needed to find a 
balance between developing overarching rules in this industry and allowing 
innovation to flourish, and that robots and robotic devices should be viewed as 
“augmenting human capabilities and empowering professionals in their role” so 
that patients would have a more positive perception of robotics in their health-
care settings [11].
Another recent study suggests that robotics lags behind its healthcare poten-
tial primarily because the industry has yet to live up to a primary principle of 
Cybernetics. According to this theory, robots and robotic devices should have a high 
level of adaptation and reaction to environments, resulting in complete interaction 
between humans and robots [12]. In this study, robotics-assisted surgery, rehabilita-
tion, prosthetics, and companion systems were analyzed.
In all areas, the study concluded, for one, that the real potential of robotics in 
these fields requires a much greater degree of customization. Customization is 
defined as the robotic technology’s adaptation to clinicians and patients, and the 
authors argue that existing robotic systems are limited in their ability for custom-
ization, which greatly limits its practical use in healthcare. The idea is that technol-
ogy should adapt to users, rather than forcing users to adapt to technology.
Despite implicit or even explicit claims of the superiority of robotic systems for 
healthcare, when compared to more traditional methods, the clear advantage of 
these systems is currently unproven and highly dependent on the skills of the users. 
Therefore, the success of such technologies is still heavily dependent on adequate 
training and experience.
8. 3D printing drugs
As our last example in this chapter of the impact of technology in medicine, 
consider the “3D” printing (3DP) of oral drugs. While it may sound novel and 
revolutionary, drug manufacturing using 3DP technology is actually a combina-
tion of well-established technologies first developed to meet the needs of engi-
neering prototypes [13], namely building objects by creating sequentially added 
layers.
There are a few driving forces behind the 3DP of oral drugs: personalization, 
on-demand capability, and the ability to manufacture drugs in new, decentralized 
locations. A recent study suggests that the key to the success of utilizing 3DP tech-
nology for healthcare and medicine is to maximize patient benefits while providing 
production efficiency, and that 3DP has a proven track record. As such, they argue, 
its future is clearly viable in three fields, namely preclinical, within a pharmaceutics 
framework; innovative drug delivery concepts; and decentralizing the drug manu-
facturing process [13].
Although this technology is currently niche and not an alternative to main-
stream mass production processes, there is a clear place for 3DP in healthcare and 
medicine and its role will be more clearly defined in the future by incorporating 
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considerations such as ideal population product profile, drug formulation, and 
engineering, as well as the management of regulatory and supply chain factors [13].
9. How to engage the patient to the human-machine innovation?
Due to the technological advances described above along with the growing 
need for smarter, preventive, more accurate, and effective medicine, the health-
care industry is advancing into the digital age—the digital health revolution. The 
digital health revolution is made possible by advances in medical information 
 technologies—information storage, data analysis, mobile, sensors, and genetic 
information. All this will enable the capture and analysis of vast amounts of infor-
mation about patients, populations, environments, and the lifestyle in which they 
live, and thus adapt personalized treatment accordingly.
The technological advances facilitating personalized medicine enable the 
capture of major challenges of the health system and chronic diseases [3]. The 
reason that chronic diseases are the major financial burden on the healthcare system 
is because most chronic disorders develop outside healthcare settings, and patients 
with these conditions require continuous interventions to make behavioral and 
lifestyles changes needed to effectively manage the disease.
The challenge with chronic diseases is the transition from health to disease 
with late-onset symptoms that can be irreversible. Coincidentally, the majority 
of chronic diseases can be prevented or delayed in life through interventions as 
described above, which results in an extended health span (the duration of indi-
vidual life spent in a state of wellness, free of disease). Current chronic disease 
management is characterized by fragmented interventions and communication and 
recommendations from specialists, becoming constitutive only following the onset 
of disease symptoms. At the stage where an individual is free of symptoms, preven-
tive activities management is done mostly by individuals themselves.
Due to the growing evidence that links patients’ activation, defined as the 
patients’ willingness and ability to take independent actions to manage their health 
and care, to their health and cost outcomes, methods and tools need to be developed 
to increase patient activation and engagement to accelerate the needed behavior 
change.
Encompassing both the design thinking approach and behavioral economics can 
motivate people to change their current behavioral health-related habits to improve 
their health. This underscores the need to devise a personalized, preventive medi-
cal infrastructure with recommendations and motivation mechanisms taken from 
behavioral economics.
Behavioral economics aims at realizing the human irrational decision process 
underpinning suboptimal outcomes, which in our context translates to unhealthy 
behavior patterns. In recent years, government agencies around the world have 
been employing behavioral economics models and methods as complementing 
means to standard public-policy tools that are implemented by decision-makers. 
These measures, based on the “Nudge” theory [14], are used for preventing policy-
implementation failures and positively impacting motivation and decision-making 
by individuals and groups. Thus far, this theory has inspired a variety of applica-
tions in areas such as education, health, safety and environment. Extensive applied 
research, performed in the UK by the Department for Environment, Food & Rural 
Affairs [15], has outlined nine principles influencing human behavior, based on 
research in social psychology and behavioral economics.
Integrating elements from persuasive technologies for supporting extrinsic 
motivation factors stemming from communication and social aspects, such as 
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incentives and norms, will have a great impact on the implantation and engage-
ment of the patient. These technologies provide effective means for supporting the 
operationalization of “Nudge” theory, for example by producing email messages for 
raising awareness regarding fulfillment of required assignments, delivering infor-
mative messages related to the performance of these assignments, and promoting a 
climate that reflects social norms within online social networks. Studies have shown 
that nudging could also incorporate various approaches that focus on changing 
physical or social environments to increase the likelihood of certain behaviors. This 
could include the provision of social norm feedback, which will increase the likeli-
hood of healthy behaviors, altering the defaults surrounding how food and drinks 
are served, or even changing the layout of buildings to encourage physical activity 
([16]: p. 263). Nudging focuses on a set of simple and low-cost remedies that may 
not require any legislation and can be used to solve most of the problems emanating 
from human contact. On the other hand, nudging could also enhance behaviors that 
may worsen the health of individuals ([16]: p. 264). For instance, food products 
may be labeled as healthy, hence causing consumers to ignore the energy content, 
which may lead to excessive consumption of such products.
The value of technologies that increase patient activation and engagement is 
paramount due to the increasing incidence of chronic diseases. Therefore, develop-
ing “patient-centered” technologies will increase adoption and diffusion of these 
technologies.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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